The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic Antibodies
Open accessAbstract
BACKGROUND: Natural killer cells are an important component of the innate immune system. Anti-cancer therapies utilizing monoclonal antibodies also rely on the cytotoxicity of NK cells for their effectiveness. Here, we study the dynamics of NK cell cytotoxicity. METHODOLOGY/PRINCIPAL FINDINGS: We observe that IL-2 activated human NK cells can serially hit multiple targets. Using functional assays, we demonstrate that on an average, a single IL-2 activated NK cell can kill four target cells. Data using live video microscopy suggest that an individual NK cell can make serial contacts with multiple targets and majority of contacts lead to lysis of target cells. Serial killing is associated with a loss of Perforin and Granzyme B content. A large majority of NK cells survive serial killing, and IL-2 can replenish their granular stock and restore the diminished cytotoxicity of 'exhausted' NK cells. IL-2 and IL-15 are equally effective in enhancing the killing frequency of resting NK cells. Significantly, Rituximab, a therapeutic monoclonal antibody increases the killing frequency of both resting and IL-2 activated NK cells. CONCLUSION/SIGNIFICANCE: Our data suggest that NK cell-based therapies for overcoming tumors rely on their serial killing ability. Therefore, strategies augmenting the killing ability of NK cells can boost the immune system and enhance the effectiveness of monoclonal antibody-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 5×
“The effectiveness of rituximab relies on the cytotoxic function of NK cells [9,10,16,17].”
BackgroundInfluentialNATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.189 · Cited by 2,113
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Bryceson, Y. T., March, M. E., Ljunggren, H.-G., & Long, E. O. (2006) · Blood · doi:10.1182/blood-2005-04-1351 · Cited by 863
The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal
Lieberman, J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1083 · Cited by 789
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Bryceson, Y. T., March, M. E., Barber, D. F., Ljunggren, H.-G., & Long, E. O. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051143 · Cited by 515
Waldmann, T. (2001) · Immunity · doi:10.1016/s1074-7613(09)00091-0 · Cited by 434
Monoclonal antibodies as therapeutic agents for cancer
Harris, M. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01467-6 · Cited by 320
Wiedemann, A., Depoil, D., Faroudi, M., & Valitutti, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600651103 · Cited by 183
Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
Gluck, W. L., Hurst, D., Yuen, A., Levine, A. M., Dayton, M. A., Gockerman, J. P., Lucas, J., Denis-Mize, K., Tong, B., Navis, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1087-3 · Cited by 166
Target-induced inactivation and cell death by apoptosis in a subset of human NK cells
Jewett, A., & Bonavida, B. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.3.907 · Cited by 139
Wülfing, C., Purtic, B., Klem, J., & Schatzle, J. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1336920100 · Cited by 123
Thorn, R. M., & Henney, C. S. (1976) · PubMed · Cited by 116
Kinetic Analysis of Target Cell Destruction by Effector T Cells
Thorn, R. M., & Henney, C. S. (1976) · The Journal of Immunology · doi:10.4049/jimmunol.117.6.2213 · Cited by 104
Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2
Eisenbeis, C. F., Grainger, A., Fischer, B., Baiocchi, R. A., Carrodeguas, L., Roychowdhury, S., Chen, L., Banks, A. L., Davis, T. A., Young, D. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0525 · Cited by 84
Cited by
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
“The synapses between NK cells and their targets are brief, allowing the NK cell to detach and engage other potential target cell”
BackgroundNatural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Mechanisms of natural killer cell-mediated cellular cytotoxicity
Prager, I., & Watzl, C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0718-269r · Cited by 627
Self-citationFormation and function of the lytic NK-cell immunological synapse
Orange, J. S. (2008) · Nature Reviews Immunology · doi:10.1038/nri2381 · Cited by 610
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Metadata
- Authors
- Bhat, R., & Watzl, C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-03-28
- Volume
- 2
- Issue
- 3
- Pages
- e326
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2033296826
- Cited by
- 286
- References
- 18
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.